Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Mills, Jeffrey H ^a   Alabanza, Leah M ^a   Mahamed, Deeqa A ^a   Bynoe, Margaret S ^a  

^a Animal Health Diagnostic Center   (United States)

Author keywords

A2A adenosine receptor; CD73; Choroid plexus; CX3CL1 (fractalkine); Experimental autoimmune encephalomyelitis; Extracellular adenosine; Multiple sclerosis; Neuroinflammation

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE A2A RECEPTOR; FRACTALKINE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOROID PLEXUS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; NUCLEIC ACID SYNTHESIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WILD TYPE;

EID: 84864795534     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-193     Document Type: Article

References (55)

1. Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review. Histol Histopathol 2004, 19:535-564.
2. Stolp HB, Dziegielewska KM. Review: Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol Appl Neurobiol 2009, 35:132-146. 10.1111/j.1365-2990.2008.01005.x, 19077110.
3. Galea I, Bechmann I, Perry VH. What is immune privilege (not)?. Trends Immunol 2007, 28:12-18. 10.1016/j.it.2006.11.004, 17129764.
4. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002, 53:285-302. 10.1146/annurev.med.53.082901.103909, 11818475.
5. Runia TF, van Pelt-Gravesteijn ED, Hintzen RQ. Recent Gains in Clinical Multiple Sclerosis Research. CNS Neurol Disord Drug Targets 2012, 5:497-505.
6. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 2001, 108:1097-1104. 209539, 11602615.
7. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985, 1:1313-1315.
8. Buljevac D, Verkooyen RP, Jacobs BC, Hop W, van der Zwaan LA, van Doorn PA, Hintzen RQ. Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patients. Ann Neurol 2003, 54:828-831. 10.1002/ana.10759, 14681894.
9. Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, van Der Meche FG, van Doorn PA, Hintzen RQ. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002, 125:952-960. 10.1093/brain/awf098, 11960885.
10. Birnbaum G. Current and future treatments for relapsing-remitting multiple sclerosis. Curr Opin Drug Discov Devel 2010, 13:214-225.
11. Clerico M, Rivoiro C, Contessa G, Viglietti D, Durelli L. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clin Neurol Neurosurg 2008, 110:878-885. 10.1016/j.clineuro.2007.10.020, 18164542.
12. Motte S, Communi D, Pirotton S, Boeynaems JM. Involvement of multiple receptors in the actions of extracellular ATP: the example of vascular endothelial cells. Int J Biochem Cell Biol 1995, 27:1-7. 10.1016/1357-2725(94)00059-X, 7757878.
13. Cook SP, McCleskey EW. Cell damage excites nociceptors through release of cytosolic ATP. Pain 2002, 95:41-47. 10.1016/S0304-3959(01)00372-4, 11790466.
14. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007, 204:1257-1265. 10.1084/jem.20062512, 2118603, 17502665.
15. Fredholm BB APIJ, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001, 53:527-552.
16. Allen-Gipson DS, Spurzem K, Kolm N, Spurzem JR, Wyatt TA. Adenosine promotion of cellular migration in bronchial epithelial cells is mediated by the activation of cyclic adenosine monophosphate-dependent protein kinase A. J Investig Med 2007, 55:378-385. 10.2310/6650.2007.00019, 18062899.
17. Naganuma M, Wiznerowicz EB, Lappas CM, Linden J, Worthington MT, Ernst PB. Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J Immunol 2006, 177:2765-2769.
18. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol 2008, 32:527-535.
19. Mills JH, Kim DG, Krenz A, Chen JF, Bynoe MS. A2A Adenosine Receptor Signaling in Lymphocytes and the Central Nervous System Regulates Inflammation during Experimental Autoimmune Encephalomyelitis. J Immunol 2012, 188:5713-5722. 10.4049/jimmunol.1200545, 22529293.
20. Mills JH, Thompson LF, Mueller C, Waickman AT, Jalkanen S, Niemela J, Airas L, Bynoe MS. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2008, 105:9325-9330. 10.1073/pnas.0711175105, 2453691, 18591671.
21. Carman AJ, Mills JH, Krenz A, Kim DG, Bynoe MS. Adenosine receptor signaling modulates permeability of the blood-brain barrier. J Neurosci 2011, 31:13272-13280. 10.1523/JNEUROSCI.3337-11.2011, 3328085, 21917810.
22. Mills JH, Alabanza L, Weksler BB, Couraud PO, Romero IA, Bynoe MS. Human brain endothelial cells are responsive to adenosine receptor activation. Purinergic Signal 2011, 7:265-273. 10.1007/s11302-011-9222-2, 3146641, 21484089.
23. Brown DA, Sawchenko PE. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J Comp Neurol 2007, 502:236-260. 10.1002/cne.21307, 17348011.
24. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli A, Lanzavecchia A, Engelhardt B, Sallusto F. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009, 10:514-523.
25. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997, 91:521-530. 10.1016/S0092-8674(00)80438-9, 9390561.
26. Broux B, Pannemans K, Zhang X, Markovic-Plese S, Broekmans T, Eijnde BO, Van Wijmeersch B, Somers V, Geusens P, van der Pol S, et al. CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients. J Autoimmun 2012, 38:10-19. 10.1016/j.jaut.2011.11.006, 22123179.
27. Kastenbauer S, Koedel U, Wick M, Kieseier BC, Hartung HP, Pfister HW. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J Neuroimmunol 2003, 137:210-217. 10.1016/S0165-5728(03)00085-7, 12667665.
28. Rancan M, Bye N, Otto VI, Trentz O, Kossmann T, Frentzel S, Morganti-Kossmann MC. The chemokine fractalkine in patients with severe traumatic brain injury and a mouse model of closed head injury. J Cereb Blood Flow Metab 2004, 24:1110-1118.
29. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000, 20:4106-4114. 10.1128/MCB.20.11.4106-4114.2000, 85780, 10805752.
30. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, Colgan SP. Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med 2004, 200:1395-1405. 10.1084/jem.20040915, 1237012,1237012, 15583013.
31. Bynoe MS, Evans JT, Viret C, Janeway CA. Epicutaneous immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis. Immunity 2003, 19:317-328. 10.1016/S1074-7613(03)00239-5, 14499108.
32. Menheniott TR, Charalambous M, Ward A. Derivation of primary choroid plexus epithelial cells from the mouse. Methods Mol Biol 2010, 633:207-220. 10.1007/978-1-59745-019-5_15, 20204630.
33. Muller DM, Pender MP, Greer JM. Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis. Curr Drug Targets Inflamm Allergy 2004, 3:279-290. 10.2174/1568010043343732, 15379596.
34. Steffen BJ, Breier G, Butcher EC, Schulz M, Engelhardt B. ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro. Am J Pathol 1996, 148:1819-1838. 1861637, 8669469.
35. Fredholm BB, Ijzerman AP, Jacobson KA, Linden J, Muller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev 2011, 63:1-34. 10.1124/pr.110.003285, 3061413, 21303899.
36. Yan L, Burbiel JC, Maass A, Muller CE. Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 2003, 8:537-576. 10.1517/14728214.8.2.537, 14662005.
37. Ciruela F, Casado V, Rodrigues RJ, Lujan R, Burgueno J, Canals M, Borycz J, Rebola N, Goldberg SR, Mallol J, et al. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 2006, 26:2080-2087. 10.1523/JNEUROSCI.3574-05.2006, 16481441.
38. Mistry G, Drummond GI. Adenosine metabolism in microvessels from heart and brain. J Mol Cell Cardiol 1986, 18:13-22.
39. Redzic ZB, Biringer J, Barnes K, Baldwin SA, Al-Sarraf H, Nicola PA, Young JD, Cass CE, Barrand MA, Hladky SB. Polarized distribution of nucleoside transporters in rat brain endothelial and choroid plexus epithelial cells. J Neurochem 2005, 94:1420-1426. 10.1111/j.1471-4159.2005.03312.x, 16111480.
40. Dale N, Frenguelli BG. Release of adenosine and ATP during ischemia and epilepsy. Curr Neuropharmacol 2009, 7:160-179. 10.2174/157015909789152146, 2769001, 20190959.
41. Pearson T, Damian K, Lynas RE, Frenguelli BG. Sustained elevation of extracellular adenosine and activation of A1 receptors underlie the post-ischaemic inhibition of neuronal function in rat hippocampus in vitro. J Neurochem 2006, 97:1357-1368. 10.1111/j.1471-4159.2006.03823.x, 16696848.
42. Schwarz N, Pruessmeyer J, Hess FM, Dreymueller D, Pantaler E, Koelsch A, Windoffer R, Voss M, Sarabi A, Weber C, et al. Requirements for leukocyte transmigration via the transmembrane chemokine CX3CL1. Cell Mol Life Sci 2010, 67:4233-4248. 10.1007/s00018-010-0433-4, 20559678.
43. Fevang B, Yndestad A, Damas JK, Bjerkeli V, Ueland T, Holm AM, Beiske K, Aukrust P, Froland SS. Chemokines and common variable immunodeficiency; possible contribution of the fractalkine system (CX3CL1/CX3CR1) to chronic inflammation. Clin Immunol 2009, 130:151-161. 10.1016/j.clim.2008.09.002, 18938112.
44. Sunnemark D, Eltayeb S, Nilsson M, Wallstrom E, Lassmann H, Olsson T, Berg AL, Ericsson-Dahlstrand A. CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J Neuroinflammation 2005, 2:17. 10.1186/1742-2094-2-17, 1188067, 16053521.
45. Huang D, Shi FD, Jung S, Pien GC, Wang J, Salazar-Mather TP, He TT, Weaver JT, Ljunggren HG, Biron CA, et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 2006, 20:896-905. 10.1096/fj.05-5465com, 16675847.
46. Hao J, Liu R, Piao W, Zhou Q, Vollmer TL, Campagnolo DI, Xiang R, La Cava A, Van Kaer L, Shi FD. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med 2010, 207:1907-1921. 10.1084/jem.20092749, 2931174, 20696699.
47. Tsutsui S, Schnermann J, Noorbakhsh F, Henry S, Yong VW, Winston BW, Warren K, Power C. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 2004, 24:1521-1529. 10.1523/JNEUROSCI.4271-03.2004, 14960625.
48. Tsutsui S, Vergote D, Shariat N, Warren K, Ferguson SS, Power C. Glucocorticoids regulate innate immunity in a model of multiple sclerosis: reciprocal interactions between the A1 adenosine receptor and beta-arrestin-1 in monocytoid cells. FASEB J 2008, 22:786-796.
49. Quarta D, Ferre S, Solinas M, You ZB, Hockemeyer J, Popoli P, Goldberg SR. Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J Neurochem 2004, 88:1151-1158. 10.1046/j.1471-4159.2003.02245.x, 15009670.
50. Engelhardt B, Wolburg-Buchholz K, Wolburg H. Involvement of the choroid plexus in central nervous system inflammation. Microsc Res Tech 2001, 52:112-129. 10.1002/1097-0029(20010101)52:1<112::AID-JEMT13>3.0.CO;2-5, 11135454.
51. Pfeiffer F, Schafer J, Lyck R, Makrides V, Brunner S, Schaeren-Wiemers N, Deutsch U, Engelhardt B. Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis. Acta Neuropathol 2011, 122:601-614. 10.1007/s00401-011-0883-2, 3207130, 21983942.
52. Flugel A, Matsumuro K, Neumann H, Klinkert WE, Birnbacher R, Lassmann H, Otten U, Wekerle H. Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. Eur J Immunol 2001, 31:11-22. 10.1002/1521-4141(200101)31:1<11::AID-IMMU11>3.0.CO;2-G, 11169433.
53. Biber K, Klotz KN, Berger M, Gebicke-Harter PJ, van Calker D. Adenosine A1 receptor-mediated activation of phospholipase C in cultured astrocytes depends on the level of receptor expression. J Neurosci 1997, 17:4956-4964.
54. Choi IY, Lee JC, Ju C, Hwang S, Cho GS, Lee HW, Choi WJ, Jeong LS, Kim WK. A3 adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats. Am J Pathol 2011, 179:2042-2052. 10.1016/j.ajpath.2011.07.006, 21854743.
55. Goodin DS. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology 2008, 71:S8-13. 10.1212/WNL.0b013e31818f3d8b, 19064873.